Joint Infection Clinical Trial
Official title:
A Phase 1b Open-Label, Dose-Escalating Study to Evaluate the Safety and Tolerability of PLG0206 in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
The purpose of this study is to learn about the safety and effects of PLG0206 for treating periprosthetic joint infections (PJI) in conjunction with the DAIR (debridement, antibiotics and implant retention) surgical procedure for patients with periprosthetic joint infections (PJI) after total knee arthroplasty (TKA) .
Peptilogics, Inc. is developing PLG0206 for the treatment of PJIs. PLG0206 is an engineered antibacterial peptide (EAP) based on naturally-occurring antimicrobial peptides (AMPs). Recent work on PLG0206 has documented that PLG0206 is a highly effective anti-biofilm agent, in addition to its established activity against planktonic staphylococcus, both in vitro and in a murine animal model of PJI. PLG0206 will be investigated in this study for treatment of PJI in conjunction with the DAIR procedure followed by the 6-week course of antimicrobial therapy that is standard-of-care (SOC) in this indication. Patients will be followed for approximately 1 year post treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05519007 -
Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone
|
N/A | |
| Active, not recruiting |
NCT04563325 -
Oral-only Antibiotics for Bone and Joint Infections in Children
|
Phase 4 | |
| Recruiting |
NCT05341908 -
Prevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients
|
||
| Recruiting |
NCT03550911 -
Biological Collection From Samples From The Gut Microbiota In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine (CARBAMICROBIOTA)
|
||
| Completed |
NCT04440631 -
Gut Microbiome of Patients Undergoing Antibiotic Therapy for Orthopedic Device-related Infection
|
||
| Recruiting |
NCT05753215 -
Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection
|
Phase 2 | |
| Not yet recruiting |
NCT06293352 -
Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection
|
N/A | |
| Recruiting |
NCT04304885 -
Effect of Sonication on Periprosthetic Joint Infection Treatment Strategy.
|
||
| Completed |
NCT03403608 -
Subcutaneous Suppressive Antibiotic Therapy for Bone and Joint Infections
|
N/A | |
| Recruiting |
NCT03704766 -
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
|
N/A | |
| Completed |
NCT00974493 -
Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J)
|
Phase 4 | |
| Completed |
NCT03191292 -
Bacterial Epidemiology and Empirical Antibiotherapy in Patients With Prosthetic Joint Infection
|
N/A | |
| Recruiting |
NCT06191601 -
Interest in Probabilistic Antibiotic Therapy With Broad-spectrum Beta-lactams in Orthopedic Surgery
|
||
| Completed |
NCT05804058 -
Biofilm Composition as a Predictive Biomarker for Prosthetic Joint Infection
|
||
| Enrolling by invitation |
NCT04723940 -
Or v IV Antibiotics for Infection
|
Phase 3 | |
| Completed |
NCT03426761 -
Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections
|
Phase 4 | |
| Enrolling by invitation |
NCT03713528 -
Can Intraosseous Antibiotics Improve the Results of Irrigation & Debridement and Prosthetic Retention for PJI?
|
Phase 4 | |
| Completed |
NCT04948281 -
Joint Infection Following ACL Reconstruction
|
||
| Completed |
NCT06267287 -
Microbiological Structure of Pathogens of Periprosthetic Infection of Large Joints in the Post-Covid Period
|
||
| Terminated |
NCT03335592 -
Cost of Off-label Antibiotics in Osteoarticular Infections
|